Category: Ivermectin

Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities

Posted on | Posted on John Murphy | Leave a Comment on Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities

The I-TECH Randomized Clinical Trial February 18, 2022 Authors: Steven Chee Loon Lim, MRCP1; Chee Peng Hor, MSc2,3; Kim Heng Tay, MRCP4; et alAnilawati Mat Jelani, MMed5; Wen Hao Tan, MMed6; Hong Bee Ker, MRCP1; Ting Soo Chow, MRCP7;  Masliza Zaid, MMed8; Wee Kooi Cheah, MRCP6; Han Hua Lim, MRCP9; Khairil Erwan Khalid, MRCP10; Joo Thye Cheng, MRCP2; Hazfadzila Mohd Unit, MRCP11;  Noralfazita  An, MMed12; Azraai Bahari Nasruddin, MRCP13; Lee Lee Low, MRCP14; Song Weng Ryan Khoo, MRCP15; Jia Hui Loh, MRCP16; Nor Zaila Zaidan, MMed17; Suhaila Ab Wahab, MMed18; Li Herng Song, MD19; Hui Moon Koh, MClinPharm20; Teck Long King, BPharm21; Nai Ming Lai, MRCPCH22; Suresh Kumar Chidambaram, MRCP4; Kalaiarasu M. Peariasamy, MSc23;  for the I-TECH Study Group Article Information Abstract Importance  Ivermectin, an inexpensive and widely available antiparasitic drug, is […]

Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities

Posted on | Posted on John Murphy | Leave a Comment on Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities

The I-TECH Randomized Clinical Trial Authors: Steven Chee Loon Lim, MRCP1; Chee Peng Hor, MSc2,3; Kim Heng Tay, MRCP4; et al JAMA Intern Med. Published online February 18, 2022. doi:10.1001/jamainternmed.2022.0189 Key Points Question  Does adding ivermectin, an inexpensive and widely available antiparasitic drug, to the standard of care reduce the risk of severe disease in patients with COVID-19 and comorbidities? Findings  In this open-label randomized clinical trial […]

Ivermectin disinformation leads to new kinds of chaos

Posted on | Posted on John Murphy | Leave a Comment on Ivermectin disinformation leads to new kinds of chaos

BY JUSTINE COLEMAN – 09/29/21 06:00 AM EDT An avalanche of misinformation about the antiparasitic drug ivermectin’s ability to treat COVID-19 has caused a series of national problems, from increased calls to poisoning centers to a shortage of the medicine itself.  Patients have become desperate for a treatment that’s most commonly used for livestock and have taken their […]

Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines

Posted on | Posted on John Murphy | Leave a Comment on Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines

Authors: Bryant, Andrew MSc1,*; Lawrie, Theresa A. MBBCh, PhD2; Dowswell, Therese PhD2; Fordham, Edmund J. PhD2; Mitchell, Scott MBChB, MRCS3; Hill, Sarah R. PhD1; Tham, Tony C. MD, FRCP4 American Journal of Therapeutics: July/August 2021 – Volume 28 – Issue 4 – p e434-e460doi: 10.1097/MJT.0000000000001402 Abstract Background:  Repurposed medicines may have a role against the SARS-CoV-2 virus. The […]

Prophylaxis against covid-19: living systematic review and network meta-analysis

Posted on | Posted on John Murphy | Leave a Comment on Prophylaxis against covid-19: living systematic review and network meta-analysis

Authors: Jessica J Bartoszko, methodologist,1 ,*Reed A C Siemieniuk, methodologist, internist,1 ,*Elena Kum, methodologist,1 ,*Anila Qasim, methodologist,1 ,*Dena Zeraatkar, methodologist,1 ,*Long Ge, methodologist,2 ,*Mi Ah Han, methodologist,3Behnam Sadeghirad, assistant professor,1,4Arnav Agarwal, methodologist, internist,1,5Thomas Agoritsas, methodologist, internist,1,6Derek K Chu, methodologist, immunologist,1,7Rachel Couban, librarian,4Andrea J Darzi, methodologist,1Tahira Devji, methodologist,1Maryam Ghadimi, methodologist,1Kimia Honarmand, methodologist, critical care physician,8Ariel Izcovich, methodologist, internist,9Assem Khamis, data analyst,10Francois Lamontagne, methodologist, critical care physician,11Mark Loeb, methodologist, infectious disease physician,1,7Maura Marcucci, methodologist, internist,1,7Shelley L McLeod, methodologist, assistant professor,12,13Sharhzad […]

Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial

Posted on | Posted on John Murphy | Leave a Comment on Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial

Authors: Julio Vallejos, Rodrigo Zoni, María Gabriela Aguirre  Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has changed our lives. The scientific community has been investigating re-purposed treatments to prevent disease progression in coronavirus disease (COVID-19) patients. Objective To determine whether ivermectin treatment can prevent hospitalization in individuals with early COVID-19. Design, setting and participants: A […]

Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19

Posted on | Posted on John Murphy | Leave a Comment on Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19

Authors: Pierre Kory, MD,1,*Gianfranco Umberto Meduri, MD,2Joseph Varon, MD,3Jose Iglesias, DO,4 and Paul E. Marik, MD5 Background: After COVID-19 emerged on U.S shores, providers began reviewing the emerging basic science, translational, and clinical data to identify potentially effective treatment options. In addition, a multitude of both novel and repurposed therapeutic agents were used empirically and studied within […]

India’s Ivermectin Blackout

Posted on | Posted on John Murphy | Leave a Comment on India’s Ivermectin Blackout

Authors: Authored by Justus R Hope, MD. via TheDesertReview.com, Ivermectin Wins in India News of India’s defeat of the Delta variant should be common knowledge. It is just about as obvious as the nose on one’s face. It is so clear when one looks at the graphs that no one can deny it. Yet, for […]

Ivermectin for COVID-19: real-time meta analysis of 63 studies

Posted on | Posted on John Murphy | Leave a Comment on Ivermectin for COVID-19: real-time meta analysis of 63 studies

Authors: Covid Analysis, Aug 12, 2021, Version 109 — twitter personality response, added Together Trial (V1 Nov 26, 2020) •Meta analysis using the most serious outcome reported shows 73% and 86% improvement for early treatment and prophylaxis (RR 0.27 [0.16-0.44] and 0.14 [0.08-0.25]), with similar results after exclusion based sensitivity analysis, restriction to peer-reviewed studies, restriction to serious outcomes, and restriction to Randomized Controlled Trials.•61% and […]

Huge study supporting ivermectin as Covid treatment withdrawn over ethical concerns

Posted on | Posted on John Murphy | Leave a Comment on Huge study supporting ivermectin as Covid treatment withdrawn over ethical concerns

The preprint endorsing ivermectin as a coronavirus therapy has been widely cited, but independent researchers find glaring discrepancies in the data Authors: Melissa Davey The efficacy of a drug being promoted by rightwing figures worldwide for treating Covid-19 is in serious doubt after a major study suggesting the treatment is effective against the virus was […]